Evidence map›Paper›PMID 35117589›Full record

ArticleTranslational cancer research2020

Long term results of different radiotherapy techniques and fractions for esophageal squamous cell carcinoma.

Jiaying Deng, Yi Xia, Yun Chen, Qi Liu, Weiwei Chen, Kuaile Zhao

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jiaying Deng *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yi Xia *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yun ChenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Qi LiuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Weiwei ChenDepartment of Radiotherapy, Yancheng Third People's Hospital, The Affiliated Yancheng Hospital of Southeast University, The Sixth Affiliated Hospital of Nantong University, Yancheng 224000, China.
Kuaile ZhaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Shanghai Medical College of Fudan University · CNFudan University Shanghai Cancer Center · CNNantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadiotherapy plays an important role in multidisciplinary treatment of esophageal squamous cell carcinoma (ESCC). However, the long term prognosis, relapse and metastasis of patients who received radiotherapy with different radiotherapy technique and fractions were unclear. The objective of the present study was to investigate the correlation of them.

methodsSix prospective studies were conducted in succession including 475 locally advanced ESCC patients received two-dimensional (2D) and three-dimensional (3D) radiotherapy with late course accelerated hyperfractionated fraction (LCAF) and continuous accelerated hyperfractionated fraction (CAHF). Overall survival was analyzed using the Kaplan-Meier method. Research regarding the incidence of Grade 3 or higher acute radiation-related toxicity was conducted. Details of relapse and metastasis were also investigated.

resultsThe median follow-up time was 57.5 months. The overall incidence of failure was 49%. No significant survival difference was observed in both LACF

conclusionsAbout half of patients suffered local/regional failure following radiotherapy. 3DRT reduced acute radiotherapy toxicities compared with 2DRT. LCAF was more tolerant than CAHF.

Indexed as

Esophageal squamous cell carcinoma (ESCC)fractionprognosisradiotherapy

Identifiers

PMID35117589
PMCPMC8798345
OpenAlexW3017331626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.